NCT06390436View on ClinicalTrials.gov

Therapeutic Drug Monitoring-baSed adalimuMab De-escalatiOn in nOn-infecTious cHronic Uveitis

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

320

Participants

Timeline

Start Date

June 30, 2025

Primary Completion Date

May 31, 2028

Study Completion Date

May 31, 2029

Conditions
UveitisChronic Disease
Interventions
DIAGNOSTIC_TEST

Blood sample

A blood sample will be taken, in addition to blood samples taken for the usual follow-up, with 4 dry tubes for the determination of ADA and anti-ADA antibodies and for bio-collection.

DRUG

Adalimumab Injection

Adalimumab Injection

Trial Locations (11)

34090

CHU MONTPELLIER - Hôpital Saint-Eloi, Montpellier

38700

CHU Grenoble Alpes, Grenoble

42055

Chu de Saint-Etienne, Saint-Etienne

43000

CH Le Puy-en-Velay, Le Puy-en-Velay

63003

Chu Montpied, Clermont-Ferrand

69317

Hôpital de la Croix Rousse, Lyon

75012

APHP - Centre hospitalier national des Quinze-Vingts, Paris

75013

APHP - Hôpital Pitié-Salpétrière, Paris

75014

APHP - Hôpital Cochin, Paris

84000

CH Avignon, Avignon

Unknown

HCL - Hôpital Edouard Herriot, Lyon

All Listed Sponsors
collaborator

Direction Générale de l'Offre de Soins

OTHER_GOV

lead

Centre Hospitalier Universitaire de Saint Etienne

OTHER